Labcorp HoldingsLH
Recorded

Labcorp Holdings 2026 UBS Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration36 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Kevin CaliendoHealthcare IT Distribution Analyst

All right. Good morning, everybody. Welcome to day two of the UBS Global Healthcare Conference. I am Kevin Caliendo, Healthcare IT Distribution Analyst here at UBS, and we are very proud and happy to have with us management from Labcorp, Julia Wang, who is the Chief Financial Officer. Julia, thank you so much for coming down.

Julia WangCFO

Hi, Kevin. So happy to be here, and thank you for having us.

Kevin CaliendoHealthcare IT Distribution Analyst

By the way, people, on the table, there is a QR code. If you want to send in a question, feel free to do so. I have an iPad up here, and if the question is not elicited, I am happy to ask it. Let us talk a little bit about 2Q. It was a really good print, one of the best prints you have had really in years. Organic growth 5.5%, which was up sequentially, even though all of the utilization trackers were not necessarily better, which maybe suggests you took share. There was also the sixth straight quarter of margin progression. If you look back at the third quarter, what was maybe the one thing that surprised you to the upside or was better than maybe what you had thought?

Julia WangCFO

Yeah, that is right. So we delivered strong performance in the third quarter, for sure, whereby we grew revenue by 7%, expanded margin by 60 basis points, and grew adjusted EPS by 14.5%. Based on that strength and momentum, we actually raised the midpoint of our guidance ranges for revenue by $65 million and for adjusted EPS by $0.18. If I were to point out one area that has delighted me to the upside, I would have to say hands down to the continued strength in our central lab service business. As you know already, in the third quarter, we grew revenue in central lab service at an organic constant currency basis of 11.3%, and that growth was primarily driven by underlying demand, and also benefiting a bit from accelerated study starts. So, we are definitely pleased with the trajectory of central lab.

Julia WangCFO

Now, if I step back, look at the quarter and even beyond the quarter, what we find encouraging is that we delivered strong growth, we expanded margins, we raised guidance, and we have momentum. It is really the combination of all those positive indicators that reinforce for us in terms of our confidence about the durability of our growth algorithm as we head into 2027.

Kevin CaliendoHealthcare IT Distribution Analyst

That is great. The central lab number was really, really impressive. I think it was, constant currency growth was 11.3% versus what you had, 7.5% prior. When you say study starts, is this new trial starts that you were just Was it you taking share there or just happened your customers were in particular? Did the market accelerate this way? I guess what I am asking is this Labcorp specific or is it market specific? And how durable is it really? Because I know your guidance now, I believe, is high single digits, which is better than 2Q, but not quite as good as 3Q, so.

Julia WangCFO

That is right. Yes. So, if I look at the central lab business, as you were saying, in the third quarter, once again, the revenue growth at an organic constant currency basis was 11.3%, and the key driver behind that growth was underlying demand. The study starts was a little bit kind of based on the pacing of the customer that was pulled forward a bit, although that was a tailwind, but not the primary driver, for sure. And to your point, if you look at over a little bit longer period of time, Q3 year to date, CLS grew revenue constant currency organic basis about 8%. And at the end of Q3, we actually raised the full year guidance for the central lab businesses to expect a high single digit revenue growth on organic constant currency basis for 2026.

Julia WangCFO

I think equally encouraging is if you look at another indicator of the health of the business, is really the book-to-bill ratio. We delivered a 1.13 in the quarter, which translating to a 1.10 for trailing 12 months. We do not break out the specific book-to-bill for central lab and ED within our BLS segment. However, what I can reinforce is that the central lab business continues to be strong from a book-to-bill perspective, and the ED booking has continuously been improving. So, once again, the area that gives us continued optimism about that business is when I look at our customer group, the growth both in revenue as well as in booking is very broadly based, and it is also very aligned with our specialty testing focus as a company, which we can talk a little bit more during this conversation here.

Julia WangCFO

But at the end of the day, I would just say that all the indicators are giving us confidence about the continued strength and momentum in central lab as we head to execute against the outlook for the next three years.

Kevin CaliendoHealthcare IT Distribution Analyst

Can we talk about the Diagnostics business a little bit?

Kevin CaliendoHealthcare IT Distribution Analyst

Let's do that. So in the quarter, organic volumes accelerated, which everybody loved to see, right?

Kevin CaliendoHealthcare IT Distribution Analyst

It went to 3.1% quarter-over-quarter versus 1.8. Price mix slowed a little bit, and I know we asked you this on the call, I believe. Was there anything in particular about the mix that maybe prompted volumes to accelerate and price growth to decelerate a little bit versus what they had been? Adam said, "Don't read into any one quarter," but was there anything there, and how should we think about those two variables going forward, the volume versus pricing?

Julia WangCFO

Yeah, absolutely. From a Diagnostics perspective, we also delivered strong performance in the third quarter. As you were saying, if you just look at the organic revenue growth, we delivered 4.4%, and that included a volume contribution of 3.1% and a price mix contribution of 1.3%. Of course, in line with what Adam has shared in the past, when you look at the contribution of volume growth vis-a-vis price mix variability to organic revenue growth, you would want to give it a little bit of time perspective versus just one single quarter, because for a complex business like ours, inevitably, it could be having some variability from quarter to quarter, right? If you step back and start from the organic volume growth, I would say for the first three quarters, we grew about 2%.

Julia WangCFO

That strength, of course, is really at the high end of the market, right? Just from an organic perspective, if you put in acquisitions, obviously outpacing the market growth as we've laid out in our strategy. From a price mix perspective, we continue to see benefit of the increase in tests per accession, as we have been consistently in our communication. The tests per accession has been a consistent contributor to the revenue growth from an organic perspective, for sure. If you expand a little bit there, you just look at the contribution of esoteric revenue to the total Diagnostics revenue over time, it has actually been growing much faster than the routine testing. Back in the first quarter of 2024, esoteric testing accounted for 38% of total Diagnostics revenue, and that ratio has improved to about 42% in 2Q of this year.

Julia WangCFO

When you think about the key drivers behind that growth, it's absolutely in line with our strategy around leading in specialty testing. Because what we have found is that when you win in specialty testing, you tend to win in the broader testing of a patient's need, particularly when you consider our overall value proposition, right? Because we are a very comprehensive testing provider that has a menu as extensive as 6,500 tests, and we perform 750 million tests every single year to be able to serve the patients. So, to have that focus in specialty and then not only growing specialty, but also grow through this pull-through, if you will, is a very conducive place to be. For the full year, actually, we have reached the midpoint of our revenue guidance for Diagnostics.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day